Table 2.
Radiorecurrent disease characteristics before salvage MRI-guided transurethral ultrasound ablation. Bold entries indicate patients with multifocal disease
| Pt | ADT at enrolment, duration | MRI T stage |
PSA (ng/ml) | Prostate volume (cm3) | Positive Bx/Bx taken | Total length (mm) |
ISUP GGd | Likert scoree | TD (mm)e | SUVmaxe | Treatment coverage (% TPV) | Ablation pattern | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bx | Cancer | ||||||||||||
| 1 | BIC 37 mo |
2c | 1.9 | 18 | 4/6a 3/6 |
NAc | NAc |
3 3 |
4 4 |
13 15 |
7.2 11.3 |
75 | Subtotal, posterobasal region untreated |
| 2 | – | 2a | 5.5 | 37 | 3/8b | 70 | 12 | 5 | 4 | 8 | 6.8 | 25 | Right apex to midgland quadrant |
| 3 | BIC 37 mo |
2c | 7.5 | 14 | 6/6a 4/6 |
96 75 |
45 27 |
3 3 |
4 4 |
19 19 |
48.1 48.1 |
100 | Whole gland |
| 4 | – | 2b | 3.3 | 18 | 4/6b | 84 | 8 | 5 | 5 | 11 | 44.6 | 50 | RL hemiablation |
| 5 | – | 2b | 16 | 24 | 3/3b | 32 | 22 | 3 | 5 | 20 | 23.3 | 50 | LL hemiablation |
| 6 | – | 2b | 11 | 21 | 5/6b | 59 | 28 | 3 | 5 | 17 | 5.4 | 50 | RL hemiablation |
| 7 | – | 2c | 4.7 | 33 | 3/4b 4/4 |
70 50 |
21 25 |
4 2 |
4 4 |
16 9 |
17.7 8.1 |
75 | Anterior and LL hemiablation |
| 8 | DGX + BIC 19 mo |
2b | 0.1 | 24 | 1/3b | 33 | 1.5 | 4 | 5 | 12 | 7.4 | 50 | RL hemiablation |
| 9 | – | 2c | 13 | 21 | 7/9b | 101 | 33 | 5 | 5 | 20 | 10.7 | 100 | Whole gland |
| 10 | – | 2c | 9.5 | 20 | Refused Bx | – | – | – | 5 | 18 | 49.6 | 75 | Anterior and LL hemiablation |
| 11 | BIC 19 mo |
NLD | 0.1 | 16 | 1/12a | 165 | 8 | 3 | NLD | NLD | NLD | 100 | Whole gland |
ADT = androgen deprivation therapy; BIC = bicalutamide; Bx = biopsy; DGX = degarelix; ISUP GG = International Society of Urological Pathology grade group; LL = left lobe; MRI = magnetic resonance imaging; NA = not available; NLD = no lesion detected; PSA = prostate-specific antigen; Pt = patient; RL = right lobe; SUVmax = maximum standardized uptake value; TD = tumor diameter; TPV = total prostate volume.
The patient underwent systematic biopsies.
The patient underwent MRI-targeted biopsies.
The percentage of prostate cancer in the biopsy material was 40%.
Pathological determination of ISUP GG for salvage patients is not standardized because of radiation-induced changes.
The exact location of all recurrent tumors on MRI and prostate-specific membrane antigen positron emission tomography/computed tomography is shown in Supplementary Figure 1.